These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 3493434

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [NKT cell-mediated immunotherapy for hematological malignancies].
    Fujii S.
    Rinsho Ketsueki; 2007 Mar; 48(3):188-99. PubMed ID: 17441475
    [No Abstract] [Full Text] [Related]

  • 27. Local administration of interleukin-2 activates lymphocytes from tumor bearing mice to recruit host immunoreactivity and inhibit tumor growth.
    Forni G, Musso T, Santoni A, Giovarelli M.
    Prog Clin Biol Res; 1987 Mar; 244():105-14. PubMed ID: 2958866
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Use of activated natural killer cells for tumor immunotherapy in mouse and human.
    Basse PH, Whiteside TL, Herberman RB.
    Methods Mol Biol; 2000 Mar; 121():81-94. PubMed ID: 10818719
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Natural killer T cell-based cancer immunotherapy.
    van der Vliet HJ, Balk SP, Exley MA.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):5921-3. PubMed ID: 17062661
    [No Abstract] [Full Text] [Related]

  • 36. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
    Steller EP, Ottow RT, Eggermont AM, Marquet RL, Sugarbaker PH.
    Cancer Detect Prev; 1988 Oct 15; 12(1-6):81-90. PubMed ID: 3263202
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. [Interleukin 2, killer cells and cancer].
    Timonen T.
    Duodecim; 1988 Oct 15; 104(9):685-9. PubMed ID: 3049038
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.